Comparison of in vivo and in vitro mouse bioassays for botulinum toxin antagonists

Journal of Applied Toxicology

Volumn 19, Issue SUPPL. 1, 1999, Pages

  Sheridan, Robert E ^a   Deshpande, Sharad S ^a   Smith, Theresa ^b  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antitoxin; Bioassay; Botulism; Mouse; Toxin

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; TOXIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BIOASSAY; CONFERENCE PAPER; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SURVIVAL;

ANIMALS; BIOLOGICAL ASSAY; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED ICR; MUSCLE CONTRACTION;

ANIMALIA; EQUIDAE;

EID: 0033368213     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1263(199912)19:1+3.0.CO;2-1     Document Type: Conference Paper

References (22)

1. D. R. Franz, P. B. Jahrling, A. M. Friedlander, D. J. McClain, D. L. Hoover, W. R. Bryne, J. A. Pavlin, G. W. Christopher and E. M. Eitzen, Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278, 399-411 (1997).
2. L. C. Sellin, The pharmacological mechanism of botulism. Trends Pharm. Sci. 6, 80-82 (1985).
3. J. D. Black and J. O. Dolly, Interaction of labeled botulinum neurotoxins with nerve terminals. J. Cell Biol. 103, 535-544 (1986).
4. L. L. Simpson, Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev. Pharmacol. Toxicol. 26, 427-453 (1986).
5. B. Poulain, J. D. F. Wadsworth, E. A. Maisey, C. C. Shone, J. Melling, L. Tauc and J. O. Dolly, Inhibition of transmitter release by botulinum neurotoxin A. Eur. J. Biochem. 185, 197-203 (1989).
6. J. Blasi, E. R.Chapman, E. Link, T. Binz, S. Yamasaki, P. DeCamilli, T. C. Südhof, H. Niemann and R. Jahn, Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365, 160-163 (1993).
7. L. L. Simpson, The interaction between aminoquinolines and presynaptically acting neurotoxins. J. Pharmacol. Exp. Ther. 222, 43-48 (1982).
8. L. L. Simpson, J. A. Coffield and N. Bakry, Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 269, 256-262 (1994).
9. R. E. Sheridan, Protonophore antagonism of botulinum toxin in mouse muscle. Toxicon 34, 849-855 (1996).
10. S. S. Deshpande, R. E. Sheridan and M. Adler, Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 35, 433-445 (1997).
11. C. Montecucco and G. Schiavo, Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem. Sci. 18, 324-327 (1993).
12. L. L. Simpson, J. A. Coffield and N. Bakry, Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin. J. Pharmacol. Exp. Ther. 267, 720-727 (1993).
13. R. E. Sheridan and S. S. Deshpande, Interactions between heavy metal chelators and botulinum neurotoxins at the mouse neuromuscular junction. Toxicon 33, 539-549 (1995).
14. L. B. Pearce, E. R. First, R. D. MacCallum and A. Gupta, Pharmacologic characterization of botulinum toxin for basic science and medicine. Toxicon 35, 1373-1412 (1997).
15. L. L. Simpson and B. R. DasGupta, Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships. J. Pharmacol. Exp. Ther. 224, 135-140 (1983).
16. H. Sugiyama, K. Mizutani and K. H. Yang, Basis of type A and F toxicities of Clostridium botulinum strain 84. Proc. Soc. Exp. Biol. Med. 141, 1063-1067 (1972).
17. R. E. Sheridan, S. S. Deshpande, J. D. Nicholson and M. Adler, Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin. Toxicon 35, 1439-1451 (1997).
18. M. Adler, R. E. Dinterman and R. W. Wannemacher, Protection by the heavy metal chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon 35, 1089-1100 (1997).
19. P. Amersdorfer, C. Wong, S. Chen, T. Smith, S. S. Deshpande, R. E. Sheridan, R. Finnern and J. D. Marks, Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun. 65, 3743-3752 (1997).
20. M. Adler, D. A. MacDonald, L. C. Sellin and G. W. Parker, Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon 34, 237-249 (1996).
21. R. E. Sheridan and S. S. Deshpande, Cytotoxicity induced by intracellular zinc chelation in rat cortical neurons. In vitro Mol. Toxicol. 11, 161-169 (1998).
22. L. S. Siegel, A. D. Johnson-Winegar and L. C. Sellin, Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E or F. Toxicol Appl. Pharmacol. 84, 255-263 (1986).